|32.43||+1.36||+4.38%||Vol 1.92M||1Y Perf 21.53%|
|Jan 15th, 2021 16:00 DELAYED|
|- -%||- -|
|Target Price||46.91||Analyst Rating||Moderate Buy 1.63|
|Potential %||44.65||Finscreener Ranking||— -|
|Insiders Trans % 3/6/12 mo.||-100/-100/-86||Value Ranking||— -|
|Insiders Value % 3/6/12 mo.||-100/-100/-20||Growth Ranking||★★★ 52.81|
|Insiders Shares Cnt. % 3/6/12 mo.||-100/-100/-32||Income Ranking||— -|
|Market Cap||4.55B||Earnings Rating||Buy|
|Price Range Ratio 52W %||39.93||Earnings Date||25th Feb 2021|
Today's Price Range
|Earnings History||Estimate||Reported||Surprise %|
|Earnings Per End||Estimate||Revision %||Trend|
|Next Report Date||25th Feb 2021|
|Estimated EPS Next Report||-0.56|
|EPS Growth Next 5 Years %||1.00|
|Avg. Weekly Volume||999.29K|
|Avg. Monthly Volume||912.02K|
|Avg. Quarterly Volume||884.83K|
Allogene Therapeutics Inc. (NASDAQ: ALLO) stock closed at 32.39 per share at the end of the most recent trading day (a 4.38% change compared to the prior day closing price) with a volume of 1.93M shares and market capitalization of 4.55B. Is a component of indices and it is traded on NASDAQ exchange. The company belongs in the Biotechnology industry, Healthcare sector and employs 190 people. Allogene Therapeutics Inc. CEO is David D. Chang.
The one-year performance of Allogene Therapeutics Inc. stock is 21.53%, while year-to-date (YTD) performance is 28.49%. ALLO stock has a five-year performance of %. Its 52-week range is between 17.43 and 55, which gives ALLO stock a 52-week price range ratio of 39.93%
Allogene Therapeutics Inc. currently has a PE ratio of -13.00, a price-to-book (PB) ratio of 3.49, a price-to-sale (PS) ratio of -, a price to cashflow ratio of -, a PEG ratio of 2.32, a ROA of -25.31%, a ROC of -27.80% and a ROE of -27.92%. The company’s profit margin is -%, its EBITDA margin is -%, and its revenue ttm is $0.00 , which makes it $0.00 revenue per share.
Of the last four earnings reports from Allogene Therapeutics Inc., there were 4 positive earnings surprise and 0 negative earnings surprise. The company has EPS estimate of $-0.56 for the next earnings report. Allogene Therapeutics Inc.’s next earnings report date is 25th Feb 2021.
The consensus rating of Wall Street analysts for Allogene Therapeutics Inc. is Moderate Buy (1.63), with a target price of $46.91, which is +44.65% compared to the current price. The earnings rating for Allogene Therapeutics Inc. stock is Buy (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).
Allogene Therapeutics Inc. has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.
Allogene Therapeutics Inc. has a Buy technical analysis rating based on Technical Indicators (ADX : 23.24, ATR14 : 3.24, CCI20 : 357.86, Chaikin Money Flow : 90.53, MACD : 0.22, Money Flow Index : 63.48, ROC : 21.58, RSI : 68.64, STOCH (14,3) : 85.78, STOCH RSI : 1.00, UO : 59.39, Williams %R : -14.22), Simple Moving Averages and Exponential Moving Averages.
Aggregated Insider Trades of Allogene Therapeutics Inc. in the last 12-months were: Alison Moore (Option Excercise at a value of $313 812), Alison Moore (Sold 128 162 shares of value $5 163 562 ), Arie S. Belldegrun (Buy at a value of $6 879 954), David D. Chang (Sold 20 335 shares of value $392 615 ), Eric Schmidt (Sold 50 450 shares of value $1 737 591 ), Rafael Amado (Sold 16 538 shares of value $651 515 ), Veer Bhavnagri (Option Excercise at a value of $253 105), Veer Bhavnagri (Sold 66 553 shares of value $2 448 087 )
Copyright (c) 2021. All rights reserved. Before deciding to trade you should carefully consider your investment objectives, level of experience and your risk appetite. Forex and Tradegate data is a real-time with a 30 second refresh. Prices may not be accurate and may differ from the actual market price. Prices on the website are indicative and solely for informational purposes, not for trading purposes or advice. Please be aware of the risks associated with trading the on financial markets, it is one of the riskiest investment forms. Past performance does not guarantee future profits. We take no responsibility for any losses that may arise as a result of the data contained on this website. The content and the website are provided "as is", without any warranties. In no event will Finscreener.com, its employees, owners, directors, affiliates, partners, data provider, third party or anyone else liable to anyone else for any decision made regarding information on this website.
This could take some time, please wait.